** Shares of drug developer Praxis Precision Medicines PRAX.O fall 39.2% to $39.51 premarket, set to open at an over eight-month low
** Co says an independent committee has recommended stopping its tremor drug trial, as it was unlikely to meet the main goal of the study; PRAX says it will continue the trial with changes to its analysis methods
** The experimental drug, ulixacaltamide, is being tested in the late-stage study to treat essential tremor, a condition that affects the nervous system and causes involuntary and rhythmic shaking
** Stock has risen 33.1% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。